262 related articles for article (PubMed ID: 26831328)
21. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Stumpo C; Rybak MJ
J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
23. Oritavancin--an investigational glycopeptide antibiotic.
Ward KE; Mersfelder TL; LaPlante KL
Expert Opin Investig Drugs; 2006 Apr; 15(4):417-29. PubMed ID: 16548791
[TBL] [Abstract][Full Text] [Related]
24. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
[TBL] [Abstract][Full Text] [Related]
25. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Crandon J; Nicolau DP
Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
[TBL] [Abstract][Full Text] [Related]
26. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
Smith JR; Roberts KD; Rybak MJ
Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
[TBL] [Abstract][Full Text] [Related]
27. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
[TBL] [Abstract][Full Text] [Related]
28. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
Poulakou G; Giamarellou H
Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
[TBL] [Abstract][Full Text] [Related]
29. Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments.
Lupia T; De Benedetto I; Bosio R; Shbaklo N; De Rosa FG; Corcione S
Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109488
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study.
Van Hise NW; Chundi V; Didwania V; Anderson M; McKinsey D; Roig I; Sharma A; Petrak RM
Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):41-45. PubMed ID: 32588385
[TBL] [Abstract][Full Text] [Related]
31. Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
[TBL] [Abstract][Full Text] [Related]
32. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
33. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T
Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
Chang JD; Foster EE; Thadani AN; Ramirez AJ; Kim SJ
J Bacteriol; 2017 Aug; 199(15):. PubMed ID: 28507244
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
Chastain DB; Davis A
Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
[TBL] [Abstract][Full Text] [Related]
36. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
[TBL] [Abstract][Full Text] [Related]
37. New agents approved for treatment of acute staphylococcal skin infections.
Tatarkiewicz J; Staniszewska A; Bujalska-Zadrożny M
Arch Med Sci; 2016 Dec; 12(6):1327-1336. PubMed ID: 27904526
[TBL] [Abstract][Full Text] [Related]
38. Oritavancin: mechanism of action.
Zhanel GG; Schweizer F; Karlowsky JA
Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851
[TBL] [Abstract][Full Text] [Related]
39. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
40. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
